Roquefort Therapeutics plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Darrin Disley, was filed 24 Nov 2025.
Roquefort Therapeutics plc: what insiders have been doing
Roquefort Therapeutics plc is a listed company. Its directors and officers file their transactions with RNS (LSE). From 22 October 2025 to 22 October 2026, the disclosure feed for Roquefort Therapeutics plc logged 1 filing by 1 insider.
The flow runs one way only: 1 insider bought (1 purchase totalling €96k) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Darrin Disley filed the largest purchase, €96k, on 24 November 2025. Among those who bought: 1 chief executive.
Compared with its exchange (832 companies, median 6 filings), a count of 1 filing is below the norm. The full history, which starts in 2022, counts 12 purchases against no sales.
The clock since the last published purchase (24 November 2025) now reads 349 days.
Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 5,000,000 shares@ £0.017100.0% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:41248828-5b93-494b-99bf-e9ff4ba7cb6eCanonical exit: 19 Feb 2026 (T+90)
- 2,400,000 shares@ £0.01563.6% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5726418Canonical exit: 2 Oct 2025 (T+90)
- 72,507 shares@ £0.013728.7% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5715997Canonical exit: 25 Sept 2025 (T+90)
- 400,000 shares@ £0.025718.8% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5526077-0Canonical exit: 5 May 2025 (T+90)
- 191,059 shares@ £0.026100.0% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5526077-1
- 269,935 shares@ £0.0735100.0% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4855132Canonical exit: 30 Oct 2023 (T+90)
- 0London Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4833327Canonical exit: 10 Oct 2023 (T+90)
- 35,921 shares@ £0.069371.3% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4814686Canonical exit: 24 Sept 2023 (T+90)
- 144,117 shares@ £0.06917.6% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4814253Canonical exit: 24 Sept 2023 (T+90)
- 028,715 purchased off-market 6,550 purchased on London Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4814176Canonical exit: 21 Sept 2023 (T+90)
- 60,415 shares@ £0.082857.9% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15FCA-NSM:4524276-1Canonical exit: 26 Dec 2022 (T+90)
- 515,913 shares@ £0.077100.0% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15FCA-NSM:4522076Canonical exit: 25 Dec 2022 (T+90)
- 210,000 shares@ £0.085224.0% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15FCA-NSM:4427952Canonical exit: 2 Oct 2022 (T+90)
13 of 13 declarations
About Roquefort Therapeutics plc
Roquefort Therapeutics plc is a company listed on the XLON market, focused on developing innovative therapeutic treatments. It aims to provide solutions for serious and unmet medical needs.
